0
U.S. (TOLL FREE)
+1 (315) 215-3225
Automative

0
U.S. (TOLL FREE)
+1 (315) 215-3225
United States Influenza Vaccines Market Report, Analysis and Forecast to 2025
Published Date: February 2019
|
Report Code: DPIR-Vacc-01
Home | Market Reports | Health | Health Conditions | Infectious Diseases
United States Influenza Vaccines Market 2013 2025

United States Influenza Vaccines Market Report, Analysis and Forecast to 2025

Code: DPIR-Vacc-01
Report
February 2019
130 Pages
DPI Research
Region: North America, South America,
Description
Table of Content
Tables & Figures

United States Influenza Vaccines market is set to touch US$ 3.5 Billion threshold by 2025.

“United States Influenza Vaccines Market Report, Analysis and Forecast to 2025” presents an in-depth assessment of the United States influenza vaccines market dynamics, opportunities, future roadmap, competitive landscape and discusses major trends. The report offers the most up-to-date industry data on the actual market situation and future outlook for United States influenza vaccines market. The report includes historic data from 2013 to 2017 and forecasts until 2025.

The report contains a granular analysis of the present industry situations, market demands, reveal facts on the market size, revenues and provides forecasts through 2025.The report provides clear insight into current and future developments of the united states influenza vaccines market. The report also explores detailed analysis of number of children and adults vaccinated with influenza vaccines in United States from 2013 to 2017 and forecasts to 2025. The report also details the latest information about the influenza vaccines production, supply, and allocation by major companies in United States.

A comprehensive analysis has been done on pricing, distribution & demand and effectiveness of influenza vaccines in United States. It also provides a deep and thorough evaluation of distribution channel & technique of influenza vaccination. It covers reimbursement pattern and offers a clear view of the regulatory landscape. Additionally, the report includes assessment of clinical trials, promising influenza vaccines in the clinical development and rapid diagnostic testing for the management of influenza. Key trends in terms of collaboration, merger & acquisition, distribution, exclusive and licensing agreement are analyzed with details. The report also explores detailed description of growth drivers and inhibitors of the United States influenza vaccines market.

The report concludes with the profiles of major players in the United States influenza vaccines market. The key market players are evaluated on various parameters such as company overview, influenza vaccines portfolios, sales value analysis and recent development of influenza vaccine market. Other emerging players such as Novavax, Daiichi–Sankyo, Mitsubishi TanabePharma and Biondvax Pharmaceuticals Ltd, are making novel technology-based influenza vaccines which is likely to affect the market share during the forecast period.

The major companies dominating this market for its products, services and continuous product developments are:

Seqirus, Sanofi Pasteur, GlaxoSmithKline (GSK) and AstraZeneca

The Latest Industry Data Included in this Report:

• United States Influenza Vaccines Market Size & Analysis (2013 - 2025)
• United States Number of Persons Vaccinated with Influenza Vaccines (2013 - 2025)
• United States Number of Children Vaccinated with Influenza Vaccines (2013 - 2025)
• United States Number of Adults Vaccinated with Influenza Vaccines (2013 - 2025)
• United States Influenza Vaccines Pricing Trends & Analysis
• United States Influenza Vaccines Production, Supply, and Allocation (By Companies)
• United States Influenza Vaccines Distribution & Demand (2010 - 2018)
• Effectiveness of Influenza Vaccines in United States (2004 – 2018)
• Rapid Diagnostic Testing for the Management of Influenza
• Distribution Channel & Technique of Influenza Vaccination in United States
• United States Influenza Vaccines Reimbursement Policies & Regulatory System
• Major Deals in United States Influenza Vaccines Market
• Promising Influenza Vaccines in Clinical Development
• Influenza Vaccines Clinical Trial Insights by Phase, Company & Country
• Market Definition for the Specified Topic Along with Identification of Key Driver and Inhibitors for the Market
• A Comprehensive List of Key Market Players Along with the Analysis of their Current
Vaccines Portfolios, Sales Value Analysis and Recent Development


Key questions answered in this research report:

• At what pace is the influenza vaccines market growing in United States? What will be growth trend in future?
• How much number of persons being vaccinated with influenza vaccines during 2013 - 2025?
• What are the key drivers and inhibitors in the current market? What will be the impact of drivers and inhibitors in the future?
• What are the various influenza vaccines available in the United States?
• How is the market predicted to develop in the future?
• Who are the key players in this market space?

  1. Executive Summary

    2. United States Influenza Vaccines Market Size & Analysis (2013 - 2025)

    3. United States Number of Persons Vaccinated with Influenza Vaccines (2013 - 2025)
    3.1 Number of Children Vaccinated with Influenza Vaccines
    3.2 Number of Adults Vaccinated with Influenza Vaccines

    4. Key Drivers and Inhibitors of the United States Influenza Vaccines Market
    4.1 Market Drivers
    4.2 Market Inhibitors

    5. United States Influenza Vaccines Pricing Trends & Analysis

    6. United States Influenza Vaccines Production, Supply, and Allocation (By Companies)

    7. United States Influenza Vaccines Distribution & Demand (2010 - 2018)

    8. Effectiveness of Influenza Vaccines in United States (2004 – 2018)

    9. Rapid Diagnostic Testing for the Management of Influenza

    10. Distribution Channel & Technique of Influenza Vaccination in United States

    11. United States Influenza Vaccines Reimbursement Policies & Regulatory System
    11.1 Reimbursement Policies
    11.2 Regulation System

    12. Major Deals in United States Influenza Vaccines Market
    12.1 Merger & Acquisitions
    12.2 Collaboration Deal
    12.3 Licensing Agreement
    12.4 Exclusive Agreement
    12.5 Distribution Agreement

    13. Promising Influenza Vaccines in Clinical Development

    14. Influenza Vaccines Clinical Trial Insights by Phase, Company & Country
    14.1 Year 2018
    14.2 Year 2017

    15. Key Companies Analysis
    15.1 Sanofi Pasteur
    15.1.1 Business Overview
    15.1.2 Influenza Vaccines Portfolio
    15.1.3 Influenza Vaccine Value Sales Analysis
    15.1.4 Recent Development
    15.2 GlaxoSmithKline (GSK)
    15.2.1 Business Overview
    15.2.2 Influenza Vaccines Portfolio
    15.2.3 Influenza Vaccine Sales Value Analysis
    15.2.4 Recent Development
    15.3 Seqirus
    15.3.1 Business Overview
    15.3.2 Influenza Vaccines Portfolios
    15.3.3 Recent Development
    15.4 AstraZeneca
    15.4.1 Business Overview
    15.4.2 Influenza Vaccines Portfolio
    15.4.3 Influenza Vaccine Sales Value Analysis
    15.4.4 Recent Development

List of Tables

Table 4–1: BiondVax Pharmaceuticals Ltd. Clinical Trials
Table 5–1: United States Pediatric Influenza Vaccines Price, 2018 – 2019
Table 5–2: United States Adult Influenza Vaccine Price, 2018 – 2019
Table 6–1: United States Influenza Vaccines Production, Supply, and Allocation
Table 7–1: Total Percentage of Influenza Vaccines Released by Week,2017 – 2018
Table 7–2: Total Percentage of Influenza Vaccines Released by Week,2016 – 2017
Table 7–3: Total Percentage of Influenza Vaccines Released by Week,2015 – 2016
Table 7–4: Total Percentage of Influenza Vaccines Released by Week,2014 – 2015
Table 8–1: Adjusted Vaccine Effectiveness Estimates for Influenza Seasons, 2004 – 2018
Table 9–1: Influenza Virus Testing Methods
Table 10–1: Distribution of Influenza Vaccination
Table 11–1: United States Simplified Regulatory Pathway from Preclinical to the Marketing Authorization
Table 12–1: Merger & Acquisitions in Influenza Vaccines Market (Million US$),2003 – 2017
Table 12–2: Collaboration Deal in Influenza Vaccines Market,2007 – 2018
Table 12–3: Licensing Agreement in Influenza Vaccines Market,2007 – 2018
Table 12–4: Exclusive Agreement in Influenza Vaccines Market,2009 – 2016
Table 12–5: Distribution Agreement in Influenza Vaccines Market,2005 – 2016

List of Figures

Figure 2–1: United States Influenza Vaccines Market (Million US$),2013 – 2017
Figure 2–2: United States Influenza Vaccines Market Forecast (Million US$),2018 – 2025
Figure 3–1: United States Total Number of Persons Vaccinated with Influenza Vaccines (Thousand), 2013 – 2017
Figure 3–2: United States Total Number of Persons Vaccinated with Influenza Vaccines Forecast (Thousand), 2018 – 2025
Figure 3–3: United States Number of Children Vaccinated with Influenza Vaccines (Thousand),2013 – 2017
Figure 3–4: United States Number of Children Vaccinated with Influenza Vaccines Forecast (Thousand),2018 – 2025
Figure 3–5: United States Number of Adults Vaccinated with Influenza Vaccines (Thousand),2013 – 2017
Figure 3–6: United States Number of Adults Vaccinated with Influenza Vaccines Forecast (Thousand),2018 – 2025
Figure 7–1: United States Influenza Vaccine Doses Distributed, By Season (Million),2010 – 2018
Figure 10–1: United States Place of Influenza Vaccination for Children and Adults,2017 - 2018
Figure 15–1: Sanofi Pasteur Influenza Vaccines Net Sales Value (Million US$),2013 – 2017
Figure 15–2: Sanofi Pasteur Influenza Vaccines Net Sales Value Forecast (Million US$),2018 – 2025
Figure 15–3: GSK Influenza Vaccines Net Sales Value (Million US$),2013 – 2017
Figure 15–4: GSK Influenza Vaccines Net Sales Value Forecast (Million US$),2018 – 2025
Figure 10–5: AstraZeneca Influenza Vaccines Net Sales Value (Million US$),2011 – 2015

SELECT A FORMAT
Added to Cart

Electronic (PDF)
$1390
This license allows only one user to access the PDF.

Electronic (PDF)
$2090
This license allows multiple user to access the PDF.

Electronic (PDF)
$2090
This license allows all the corporate employees to access the PDF.
Add to Cart
Buy Now (10% Discount)
OUR CUSTOMER
Bioinformatics Barcelona

RELATED REPORTS

China Autogenous Vaccines Market Report Forecast 2021 2027
China Autogenous Vaccines Market Report & Forecast 2021-2027

120 Pages
Type: Report
Code: QYRE-Auto-22Z1818
Sat Oct 02 00:00:00 UTC 2021

Add to Cart

Global Flu Vaccine Market Size Manufacturers Supply Chain Sales Channel and Clients 2021 2027
Global Flu Vaccine Market Size, Manufacturers, Supply Chain, Sales Channel and Clients, 2021-2027

In 2020 the global Flu Vaccine market size was US 5154 million and it is expected to reach US 7293.3 million by the end of 2027 with a CAGR of 4.8 during 20212027.Global Flu Vaccine Market Size Manufacturers Supply Chain Sales Channel and Clients 20212027.

120 Pages
Type: Report
Code: QYRE-Auto-11H675
Mon Sep 27 00:00:00 UTC 2021

Add to Cart

Global Rabies Vaccine Market Size Manufacturers Supply Chain Sales Channel and Clients 2021 2027
Global Rabies Vaccine Market Size, Manufacturers, Supply Chain, Sales Channel and Clients, 2021-2027

And in terms of application the largest application is Postexposure Prophylaxis followed by Preexposure Prophylaxis.Market Analysis and Insights Global Rabies Vaccine MarketIn 2020 the global Rabies Vaccine market size was US 877 million and it is expected to reach US 1178 million by the end of 2027 with a CAGR of 4.0 during 20212027.Global Rabies Vaccin.

120 Pages
Type: Report
Code: QYRE-Auto-34M23
Mon Sep 27 00:00:00 UTC 2021

Add to Cart

Global and United States Sulfachloropyridazine Sodium Market Insights Forecast to 2027
Global and United States Sulfachloropyridazine Sodium Market Insights, Forecast to 2027

120 Pages
Type: Report
Code: QYRE-Auto-28M6619
Tue Sep 21 00:00:00 UTC 2021

Add to Cart